Transfusion Medicine Reviews
Volume 22, Issue 2 , Pages 97-102 , April 2008

Pathogen Reduction: A Precautionary Principle Paradigm

  • Harvey J. Alter

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Harvey J. Alter, MD, FACP, Chief, Infectious Disease Section, Department of Transfusion Medicine, Bldg 10, Room 1C-711, NIH, 10 Center Drive, Bethesda, MD 20892.

References 

  1. Alter HJ, Houghton M. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med. 2000;6:12–16
  2. Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion. 1993;33:890–893
  3. Biggerstaff BJ, Peterson LR. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion. 2002;42:1019–1026
  4. Murphy W. Managing threats rather than risks in blood transfusion: Robust design for a complex system. Transfusion. 2006;46:2011–2013
  5. Busch MP. Transfusion transmitted viral infections: Building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion. 2006;46:1624–1640
  6. O'Brien SF, Yi Q-L, Fan W, et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion. 2007;47:316–325
  7. Centers for Disease Control and Prevention (CDC) serosurveys for West Nile virus infection—New York and Connecticut counties 2000. MMWR Morb Mortal Wkly Rep. 2001;50:37–39
  8. Stramer SL, Fang CT, Foster GA, et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353:451–459
  9. Centers for Disease Control and Prevention. Dengue Fever. www.cdc.gov/ncidod/dvbid/dengue. 12-19-2006.
  10. Pellett PE, Wright DJ, Engels EA, et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 2003;43:1260–1268
  11. Hladik W, Dollard SC, Mermin J. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006;355:1331–1338
  12. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: The role of pathogen inactivation. Transfus Med Rev. 2005;19:110–126
  13. Goodrich RP. The use of riboflavin for the inactivation of pathogens inblood products. Vox Sang. 2000;78(Suppl 2):211–215
  14. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amatosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion. 2006;46:731–740
  15. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood. 2006;107:3753–3760
  16. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood. 2003;101:2426–2433

PII: S0887-7963(08)00002-3

doi: 10.1016/j.tmrv.2008.01.001

Transfusion Medicine Reviews
Volume 22, Issue 2 , Pages 97-102 , April 2008

Article Tools